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Cox-2 and IL-10 Polymorphisms and Association with Squamous 
Cell Carcinoma of The Head and Neck in a Korean Sample
Cyclooxygenase-2 (COX-2) is involved in inflammation and carcinogenesis. Interleukin-10 
(IL-10) is also regarded as anti-inflammatory factors with the multi-functional ability to 
positively and negatively influence functional immunity and tumor development. Genetic 
polymorphisms of COX-2 and IL-10 might contribute to the development of squamous cell 
carcinoma of the head and neck (SCCHN). The purpose of this study was to evaluate the 
association of COX-2 and IL-10 single nucleotide polymorphisms (SNPs) with the risk of 
SCCHN in a Korean sample. We analyzed the COX-2 SNPs, -1329A>G, +1266C>T, and 
+6365T>C, and the IL-10 SNPs, -1082A>G, +920T>G, and +3917T>C, in 290 Korean SCCHN 
patients and 358 healthy controls. There was no significant association between the risk of 
SCCHN and the three COX-2 or three IL-10 SNPs. We analyzed three haplotypes (ht1, ht2, 
ht3) for COX-2 and found that COX-2 ht3+/+ was associated with a decreased risk of 
SCCHN in a Korean sample, compared with the COX-2 ht3 -/- genotype (P=0.03). Two 
haplotypes (ht1, ht2) of IL-10 were analyzed and there was no statistical significance in the 
distribution of haplotypes. Based on these results, the COX-2 haplotype ht3 can be used as 
a molecular biomarker to predict low risk groups of SCCHN in a Korean sample. 
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INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) is the 
fifth most common cancer worldwide and accounts for 3.5% of 
the cancers registered in Korea during 2001 (1). SCCHN is be-
lieved to be induced by environmental and host factors. The 
main causative environmental factors are tobacco or alcohol 
use, viral infection, nutritional deficit, mineral inhalation and 
history of radiation exposure (2, 3). Accumulating evidence has 
shown that genetic polymorphisms influence the risk of envi-
ronmental carcinogenesis (4-6), and that genetic susceptibility 
plays an important role in the development of SCCHN. There-
fore, it has been suggested that susceptibility to SCCHN may be 
due to genetic polymorphisms in genes controlling carcinogen 
metabolism, repair of DNA damage, or genes related to cancer 
development, such as various cytokine genes and cyclooxygen-
ase-2 (COX-2) (7-11).
  Cyclooxygenase (COX) is a key enzyme that mediates the con-
version of free arachidonic acid to prostaglandin. COX consists 
of two isoforms, COX-1 and COX-2 (12). COX-1 is constitutively 
expressed in most tissues for physiologic homeostasis. In com-
parison, COX-2 is rapidly activated by growth factors and mito-
gen and plays an important role in inflammation and tumor 
development (13).
  Interleukin-10 (IL-10) is an important immunoregulatory cy-
tokine in humans that is secreted by helper T-cells and synthe-
sized by activated macrophages (14). IL-10 has the inhibitory 
properties of inflammatory cytokines like interferon gamma, IL-
2, and IL-3, which are produced by macrophages and helper T-
cells (14). The functions of IL-10 in humans range from the anti-
inflammatory activity associated with auto-immune disease to 
tumor development and growth, as demonstrated by reports of 
increased IL-10 levels in cancer patients (14, 15).
  Recently, several polymorphisms in COX-2 and IL-10 have 
been found to be associated with inflammation and tumor de-
velopment. It is also thought that these polymorphisms may 
cause the differential expression of these genes, resulting in sus-
ceptibility to cancer development. Many studies have linked 
COX-2 and IL-10 genetic polymorphisms with various types of 
carcinoma (16, 17), but the COX-2 and IL-10 genetic polymor-
phisms have not been studied in cases of SCCHN in a Korean 
sample. In this study, we investigated the frequencies of single 
nucleotide polymorphisms (SNPs) in COX-2 and IL-10 between 
SCCHN patients and controls in a Korean sample and evaluat-
ed the effect of the COX-2 and IL-10 polymorphisms on the risk 
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MATERIALS AND METHODS 
Study population
For our hospital-based case-control study, we recruited subjects 
from the Department of Otolaryngology, Hanyang University 
Hospital, Seoul, Korea from 1997 to 2004. The case group con-
sisted of 290 cases with pathologically-verified SCCHN. The cas-
es were newly-diagnosed SCCHN patients, with the following 
primary sites: larynx (n=148), oral cavity (n=69), oropharynx (n= 
39), hypopharynx (n=39) and other (n=4). For the control group, 
we enrolled 358 hospital-based chronic otitis media, chronic si-
nusitis, and chronic tonsillitis patients. Cases and controls with 
a history of previous malignant disease or a genetic disease were 
excluded. The mean age of the case group was 62.6 yr (range, 
28-90), with 252 males and 38 females. The mean age of the con-
trol group was 38.8 yr (range, 21-76), with 339 males and 19 fe-
males. All patients and controls were of Korean ethnicity. All par-
ticipants provided informed consent. The Institutional Review 
Board of College of Medicine, Hanyang University approved the 
study protocol (December 15, 2008). Peripheral blood specimens 
were collected from all the subjects and stored at -80°C before 
DNA isolation.
Genotyping
We performed DNA extraction from peripheral blood using the 
Wizard
TM Genomic DNA purification kit (Promega, Madison, WI, 
USA). We analyzed three SNPs of COX-2 (-1329A>G, +1266C>T, 
and +6365T>C) and three SNPs of IL-10 (-1082A>G, +920T>G, 
and +3917T>C). We performed single base extension (SBE) for 
genetic analysis of all SNPs, except for COX-2 +6365T>C. The 
polymerase chain reactions (PCR) included primers (1.25 pM 
each), 5 ng genomic DNA, 250 μM dNTPs and 0.15 U Taq DNA 
polymerase (Applied Biosystems, Foster City, CA, USA) and were 
run using the GeneAmp PCR System 9700 Thermocycler (Ap-
plied Biosystems). The primers used are listed in Table 1. Using 
the SNaPshot ddNTP primer extension kit (Applied Biosystems), 
we performed the primer extension reaction. To clean-up the 
primer extension reaction products, 1 U shrimp alkaline phos-
phatase (Amersham Life Science, Cleveland, Ohio, USA) was 
added to the reaction mixture, and the mixture was incubated 
at 37°C for one hour, followed by 15 min at 72°C for enzyme inac-
tivation. We added the amplified material and Genescan 120Liz 
size-standard solution (Applied Biosystems) in Hi-Di formamide 
(Applied Biosystems) and incubated the reaction at 95°C for five 
minutes, followed by incubation on ice for five minutes. Elec-
trophoresis was performed using the reaction mixture with an 
ABI Prism 3100 Genetic Analyzer (Applied Biosystems). We used 
ABI Prism GeneScan and Genotyper to perform the genetic 
analyses. 
  The analysis of the COX-2 +6365T>C SNP was performed us-
ing the TaqMan assay. The forward and reverse primers were: 
5’-GCATCTTCCATGATGCATTAGAAGTAAC-3’ , 5’-GCACTGA–
TACCTGTTTTTGTTTGATGA-3’ . The probe for the wildtype (T 
allele) was 5’-AAGTACTTTTGGTTATTTTT-3’ . The 5’ end was 
conjugated with VIC
TM fluorescent dye and the 3’ end was con-
jugated with TAMRA
TM quencher dye. The probe for the mutant 
type (C allele) was 5’-ACTTTTGGTCATTTTT-3’ , with the 5’ end 
bound to FAM
TM fluorescent dye and the 3’ end bound to TAM-
RA
TM quencher dye. PCR was performed in a 5 μL reaction that 
consisted of a mixture of TaqMan universal PCR master mix 
(Applied Biosystems), UNG, primers (900 μM), probe (200 nM) 
and genomic DNA (20 μg). The PCR reaction conditions were 
as follows: 50°C for two minutes, 95°C for ten minutes and then 
15 sec denaturing, final annealing and extension at 60°C for one 
minute, for 40 amplification cycles. The TaqMan assay plate was 
transferred to a Prism 9700HT instrument and genetic analysis 
was performed by measuring the fluorescence level in each well.
Statistical analyses
Statistical verification of the associations of COX-2 and IL-10 
genetic polymorphisms with SCCHN and with the normal con-
trol group was performed using a chi square test. The odds ra-
tios (OR) and 95% confidence intervals were obtained using a 
logistic regression model. All statistical analyses were performed 
using the SPSS statistical package (SPSS, version 12.0, Inc., Chi-
cago, IL, USA).
RESULTS
COX-2 polymorphisms 
For the COX-2 -1329A>G SNP (genotyping was available in 621 
of 648 subjects), the frequency of variant allele G was 44.2% and 
heterozygosity was 46.8%. The frequency of the COX-2 geno-
types, -1329 AA, AG and GG, were 31.7%, 46.9%, 21.4% in the 
case group and 32.9%, 46.9%, and 20.3% in the control group  
respectively. The odds ratio and respective 95% confidence in-
Table 1. Primer sequences for COX-2 and IL-10 SNP genotyping using the single-
base extension method
Locus Primer Sequence (5´-3´)
COX-2 -1329A>G 
forward
reverse
extension
 TCCTCCCTGAGCACTACCCAT
 CAGTTGCCTGGGCTTATTGG
 GTTAAACAAAAGCAAAGATGAAATTCCA
COX-2 +1266C>T
forward
reverse
extension
 CTTCCTTCGAAATGCAATTATGAGT
 TGAGCAGACTGTATAAACTGGATGG
 CATGTAAGTACAAGTGTCTTTCTAAGGTTTTTAGC
IL-10 -1082A>G
forward
reverse
extension
 CCCAACTGGCTCCCCTTAC
 GGAGGCTGGATAGGAGGTCC
 ATGATGATACTTTCCTCTTACCTATCCCTACTTCCCC
IL-10 +920T>G
forward
reverse
extension
 TGCTTTCCCTTCAAAATCGG
 CCTTCATTTGCTGCAGGAAGA
 ATGATTTTTTTGGGCCAGAGCCAATTT
IL-10 +3917T>C
forward
reverse
extension
 GAGACATCAGGGTGGCGACT
 GGCTCCCCAAAGAACATTTTT
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tervals for the genotype AG and GG in reference to AA were  
1.08 (0.78-1.49) and 1.00 (0.61-1.65), respectively. For the COX-
2 +1266C>T SNP (genotyping was available in 621 of 648 sub-
jects), the frequency of variant allele T was 0.7% and the hetero-
zygosity was 1.4%. The frequency of the COX-2 genotypes, +1266 
CC, CT, and TT, were 97.8%, 1.8%, and 0.4% in the case group 
and 98.9%, 1.1%, and 0% in the control group, respectively. The 
relative risk of CT to CC was 1.11 (0.21-5.99). For the COX-2 
+6365T>C SNP (genotyping was available in 587 of 648 subjects), 
the frequency of variant allele C was 20.8% and heterozygosity 
was 33.2%. The frequency of the COX-2 genotypes, +6365 TT, 
TC, and CC, were 64.7%, 32.1%, and 3.2% in the case group and 
61.2%, 34%, and 4.7% in the control group, respectively. The rel-
ative risks of TC and CC to TT were 1.01 (0.55-1.84), and 0.78 
(0.49-1.26), respectively. We found no statistical significance in 
our analyses (Table 2).
COX-2 haplotypes 
We identified six haplotypes (GCT, ACT, ACC, ATC, GCC, GTT) 
for COX-2 -1329A>G, +1266C>T, and +6365T>C and analyzed 
the three most common haplotypes, which we abbreviated as 
ht1 (GCT), ht2 (ACT), and ht3 (ACC) (Table 3). The haplotype 
distributions are summarized in Table 4. 
  The frequencies of ht3 -/-, +/-, and +/+ were 69.3%, 27.8%, 2.9% 
in the case group and 62.4%, 33.0%, and 4.6% in the control group, 
respectively. The relative risk of ht3 +/- to -/- was 1.05 (0.55-2.01) 
and the relative risk of ht3+/+ to -/- was 0.60 (0.38-0.96). So, com-
pared with the ht3-/- genotype, the ht3+/+ genotype was signif-
icantly associated with a decreased risk of HNSCC in Koreans 
(P=0.03). 
IL-10 polymorphisms 
For the IL-10 -1082A>G SNP (genotyping was available in 628 of 
648 subjects), the frequency of the variant allele G was 7% and 
the heterozygosity was 13.2%. The frequencies of IL-10 genotypes, 
-1082 AA, AG, and GG, were 85.6%, 13.7%, and 0.7% in the case 
group and 86.9%, 12.9%, and 0.3% in the control group, respec-
tively. The relative risks of genotypes AG and GG to AA were 0.75 
(0.40-1.43) and 1.03 (0.28-3.81), respectively. For the IL-10 +920T> 
G SNP (genotyping was available in 609 of 648 subjects), the fre-
quency of the variant allele G was 30.3% and the heterozygosity 
was 41.2%. The genotype frequencies of TT, TG and GG were 
45.5%, 46.2%, and 8.3% in the case group and 51.6%, 37.4%, and 
11.0% in the control group, respectively. The relative risks of TG 
and GG to TT were 1.36 (0.85-2.16) and 0.88 (0.59-1.30), respec-
tively. For the IL-10 +3917T>C SNP (genotype was available in 
612 of 648 subjects), the variant allele C was 3.5% and the het-
erozygosity was 6.8%. The genotype frequencies of TT, TC, and 
Table 2. Logistical analysis of the COX-2 gene in Korean head and neck squamous cell carcinoma patients and normal control subjects
Gene Loci Genotype Cancer Normal  OR (95% CI) P
COX-2
-1329A>G
AA
AG
GG
  86 (31.7%)
127 (46.9%)
  58 (21.4%)
115 (32.8%)
164 (46.9%)
  71 (20.3%)
1
1.08 (0.78-1.49)
1.00 (0.61-1.65)
  0.64
  0.99
+1266C>T
CC
CT
TT
266 (97.8%)
  5 (1.8%)
  1 (0.4%)
345 (98.9%)
  4 (1.1%)
  0 (0.0%)
1
1.11 (0.21-5.99) 0.99
0.90
+6365T>C
TT
TC
CC
161 (64.7%)
  80 (32.1%)
  8 (3.2%)
207 (61.3%)
115 (34.0%)
16 (4.7%)
1
1.01 (0.55-1.84)
0.78 (0.49-1.26)
  0.98
  0.31
OR, odds ratio; CI, confidence interval.
Table 3. The frequencies of COX-2 gene haplotypes in Korean head and neck squamous 
cell carcinoma patients and normal control subjects
Haplotype -1329A>G +1266C>T +6365T>C Frequency
ht1 G C T 0.438
ht2 A C T 0.357
ht3 A C C 0.192
ht4 A T C 0.008
ht5 G C C 0.004
ht6 G T T 0.001
Ht, haplotype.
Table 4. Analysis of haplotypes in the COX-2 gene in Korean head and neck squamous cell carcinoma patients and normal control subjects
Gene Loci Genotype Cancer Normal  OR (95% CI) P
COX-2
ht1
-/-
ht1/-
ht1/ht1
  89 (32.1%)
129 (46.6%)
  59 (21.3%)
114 (32.5%)
171 (48.7%)
  66 (18.8%)
1
0.91 (0.66-1.26)
0.88 (0.54-1.43)
0.56
0.61
ht2
-/-
ht2/-
ht2/ht2
113 (40.8%)
124 (44.8%)
  40 (14.4%)
152 (43.3%)
153 (43.6%)
  46 (13.1%)
1
0.32 (0.92-1.89)
1.35 (0.86-2.13)
0.13
0.19
ht3
-/-
ht3/-
ht3/ht3
192 (69.3%)
  77 (27.8%)
  8 (2.9%)
219 (62.4%)
116 (33.0%)
16 (4.6%)
1
0.15 (0.55-2.01)
0.60 (0.38-0.96)
0.89
0.03
OR, odds ratio; CI, confidence interval; ht, haplotype.Jeong SW, et al.  •  COX-2 & IL-10 Polymorphisms in Head and Neck Cancer 
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CC were 92.9%, 6.8%, and 0.4% in the case group and 93.1%, 6.9%, 
and 0% in the control group, respectively. The relative risk of TC 
to TT was 0.71 (0.30-1.70). No significant statistical results were 
obtained in our analyses of IL-10 polymorphisms (Table 5).
IL-10 haplotypes
Two haplotypes, ht1(ATT) and ht2(AGT) for the IL-10 SNPs 
-1082A>G, +920T>G, and +3917T>C were analyzed. The haplo-
type distributions are summarized in Table 6. There was no sig-
nificant difference in the distribution of the two IL-10 haplotypes 
in the SCCHN patient and normal control groups. 
DISCUSSION
Development of cancer is dependent on individual genetic sus-
ceptibility. For example, genetic polymorphisms, activation of 
cancer genes and alterations of the immune system are deter-
minants of individual genetic susceptibility (18). The most com-
mon genetic polymorphism in the population is SNP, which are 
single nucleotide substitutions within genes. These small chang-
es in DNA can cause significant alterations in normal genetic 
function, metabolism, repair of DNA, personal sensitivity and 
ultimately malignant tumor development (19). 
  COX-2 expression and activity is induced by growth factors, 
carcinogens and oncogenes (20). COX-2 overexpression and its 
association with cancer development have been reported espe-
cially in colorectal cancer and SCCHN (21). The COX-2 gene is 
located at 1q25.2-q25.3 and is encoded by 10 exons (22). To date, 
25 polymorphisms in the COX2 gene have been identified in a 
Korean sample. 
  Our study analyzed the association of COX-2 SNPs 1329A>G, 
+1266C>T, +6365T>C with SCCHN in a Korean sample. There 
was no definite statistical significance between cancer risk and 
genetic polymorphism for three COX-2 SNPs. However, the fre-
quency of the haplotype ht3 (ACC) differed significantly. Haplo-
type ht3 +/+ (ACC/ACC) was associated with a significantly de-
creased risk of SCCHN, compared with the ht3-/- group, suggest-
ing a possible involvement of ht3 in the development of SCCHN. 
There has been no study that evaluates COX-2 SNPs that were 
analyzed in our study in SCCHN. In a study that examined the 
association of COX-2 -765 G>C polymorphism with the risks of 
oral squamous cell carcinoma in a Taiwan population, the au-
thors reported that COX-2 -765C allele was a protective factor 
against oral squamous cell carcinoma (23). However, in other 
study in the Netherlands, there was no risk-modifying effect of 
COX-2 -1195 A>G and -765 G>C polymorphisms in head and 
neck carcinogenesis (24). 
  IL-10 is an important immune regulatory cytokine in humans 
that is mainly secreted by helper T-cells and synthesized by ac-
tivated macrophages (14). The predominant effect of IL-10 is 
reduced inflammation, and it contributes to the control of im-
mune-related cellular proliferation and differentiation (14, 15). 
  The IL-10 gene is located on chromosome 1q31-32 and is en-
coded in 5 exons. Numerous genetic polymorphisms in IL-10 
have been reported and nearly all of them are SNPs (25). In Ital-
ian patients with undifferentiated carcinoma of the nasopharynx, 
it has been reported that IL-10 -1082A>G, -819C>T, and -592A>C 
SNPs were not associated with cancer development (26). In our 
study, we analyzed three IL-10 SNPs and two haplotypes. The 
IL-10 -1082A>G, +920T>G, and +3917T>C SNPs and their re-
spective haplotypes were not associated with the risk of SCCHN 
in a Korean sample. 
Table 5. Logistical analysis of the IL-10 gene in Korean head and neck squamous cell carcinoma patients and normal control subjects
Gene Loci Genotype Cancer Normal  OR (95% CI) P
IL-10
-1082A>G
AA
AG
GG
238 (85.6%)
  38 (13.7%)
  2 (0.7%)
304 (86.8%)
  45 (12.9%)
  1 (0.3%)
1
0.75 (0.40-1.43)
1.03 (0.28-3.81)
0.39
0.96
+920T>G
TT
TG
GG
120 (45.5%)
122 (46.2%)
22 (8.3%)
178 (51.6%)
129 (37.4%)
  38 (11.0%)
1
1.36 (0.85-2.16)
0.88 (0.59-1.30)
0.20
0.51
+3917T>C
TT
TC
CC
247 (92.8%)
18 (6.8%)
  1 (0.4%)
322 (93.1%)
24 (6.9%)
  0 (0.0%)
1
0.71 (0.30-1.70)
  
0.44
0.99
OR, odds ratio; CI, confidence interval.
Table 6. Analysis of IL-10 haplotypes in Korean head and neck squamous cell carcinoma patients and normal control subjects
Gene Loci Genotype Cancer Normal  OR (95% CI) P
IL-10
ht1
ht1/ht1
ht1/-
-/-
117 (45.3%)
121 (46.9%)
20 (7.8%)
176 (51.8%)
129 (37.9%)
  35 (10.3%)
1
1.38 (0.86-2.19)
0.81 (0.53-1.23)
0.18
0.32
ht2
-/-
ht2/-
ht2/ht2
239 (92.6%)
  9 (3.5%)
10 (3.9%)
306 (90.0%)
14 (4.1%)
20 (5.9%)
1
0.65 (0.18-2.34)
0.76 (0.46-1.26)
0.51
0.29
OR, odds ratio; CI, confidence interval; ht, haplotype.Jeong SW, et al.  •  COX-2 & IL-10 Polymorphisms in Head and Neck Cancer 
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  In conclusion, COX-2 ht3+/+ was associated with a significant-
ly decreased risk of SCCHN in a Korean sample, compared with 
the COX-2 ht3-/- genotype. Based on this result, the COX-2 hap-
lotype ht3 can be used as a molecular biomarker to predict low 
risk groups of SCCHN in a Korean sample. 
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